van Aalderen, Wim M
Garcia-Marcos, Luis
Gappa, Monika
Lenney, Warren
Pedersen, Søren
Dekhuijzen, Richard
Price, David
Article History
Received: 24 April 2014
Revised: 22 August 2014
Accepted: 24 August 2014
First Online: 8 January 2015
Competing interests
: WMvA is a member of the advisory boards of Mundipharma, Astra Zeneca, AbbVie and Teva. LGM has no conflict of interest. MG has no conflict of interest. WL has no conflict of interest. S. Pedersen has received consultancy fees from Glaxo Smith Kline and Boehringer Ingelheim, and fees for lectures for Glaxo Smth Kline and Boehringer Ingelheim. PND has received reimbursements for attending symposia, fees for speaking, organising educational events, funds for research or fees for consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi, Merck Sharp & Dohme, Mundipharma, Novartis, Takeda, Almirall and Teva. He is a member of the Aerosol Drug Management Improvement Team (ADMIT). DP has board membership at Almirall, Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Medapharma, Novartis, Napp, Nycomed, Pfizer, Sandoz and Teva. <i>Consultancy</i>: Almirall, Amgen, Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Medapharma, Novartis, Napp, Nycomed, Pfizer, Sandoz and Teva. <i>Grants/Grants Pending</i>: UK National Health Service, Aerocrine, Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Merck, Mundipharma, Novartis, Nycomed, Orion, Pfizer, Takeda, Teva and Zentiva. <i>Payments for lectures/speaking</i>: Almirall, AstraZeneca, Activaero, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Novartis, Medapharma, Merck, Mundipharma, Pfizer, SkyePharma, Takeda and Teva. <i>Payment for manuscript preparation</i>: Merck, Mundipharma and Teva. <i>Patents (planned, pending or issued)</i>: AKL Ltd. <i>Payment for the development of educational materials</i>: GlaxoSmithKline. <i>Stock/Stock options</i>: Shares in AKL Ltd, which produces phytopharmaceuticals and owns 80% of Research in Real Life Ltd and its subsidiary social enterprise Optimum Patient Care. <i>Payment for travel/accommodations/meeting expenses</i>: Aerocrine, Boehringer Ingelheim, Napp, Novartis, Mundipharma and Teva. <i>Funding for patient enrolment or completion of research</i>: Chiesi, Almirall, Zentiva and Teva. <i>Peer reviewer for grant committees</i>: Medical Research Council (2012), Efficacy and Mechanism Evaluation programme (2012), HTA (2012). <i>Contract research</i>: Aerocrine, AKL Ltd, Almirall, Boehringer Ingelheim, Chiesi, Mundipharma, Medapharma, Novartis, Napp, Orion, Takeda, Zentiva.